Spots Global Cancer Trial Database for resistance
Every month we try and update this database with for resistance cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients | NCT04222335 | Lung Cancer, No... | Blood samples | 18 Years - | University Hospital, Toulouse | |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) | NCT03532698 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Aspirin Osimertinib | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma | NCT03848676 | Multiple Myelom... | Evaluation of p... | 18 Years - | University of Turin, Italy | |
| Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma | NCT05867004 | Melanoma Immune Defect Tumor Skin | 18 Years - | Institut Claudius Regaud | ||
| Preclinical Validation of New Anti-melanoma Compounds | NCT03798977 | Melanoma | 18 Years - | Centre Hospitalier Universitaire de Nice | ||
| MYeloma Resistance And Clonal Evolution | NCT03807128 | Multiple Myelom... | No intervention... | 18 Years - | Nantes University Hospital | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital | |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | NCT02066870 | Non-small Cell ... | Icotinib Arsenic trioxid... | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) | NCT05529524 | Follicular Lymp... | 18 Years - | The Lymphoma Academic Research Organisation | ||
| OncoSNIPE - Study of Molecular Profiles Associated With the Development of Resistance in Solid Cancer Patients | NCT04548960 | CANCER | cancer patients | 18 Years - | Oncodesign SA | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | NCT01276899 | Triple Negative... | Needle core bio... Needle core bio... | 18 Years - | Jewish General Hospital | |
| Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer | NCT05020275 | Lung Cancer | Blood Samples | 18 Years - | Rennes University Hospital | |
| Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | NCT02098954 | Carcinoma, Non-... EGFR Gene Mutat... | Gemcitabine pla... | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer | NCT04289974 | Breast Cancer | Palbociclib | 18 Years - 70 Years | ChineseAMS | |
| Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer | NCT00984048 | Colorectal Canc... | Needle core bio... | 18 Years - | Jewish General Hospital | |
| Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | NCT01276899 | Triple Negative... | Needle core bio... Needle core bio... | 18 Years - | Jewish General Hospital | |
| Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. | NCT04737382 | Non-small-cell ... | biopsy ctDAN analysis | 18 Years - | The Netherlands Cancer Institute | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| TAURAS - T790 AURA ScreenFailure SOC Registry Study | NCT02405247 | Non Small Cell ... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors | NCT05853458 | Polycythemia Ve... | Hydroxyurea | 18 Years - 99 Years | Novartis | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer | NCT05020275 | Lung Cancer | Blood Samples | 18 Years - | Rennes University Hospital | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients | NCT04222335 | Lung Cancer, No... | Blood samples | 18 Years - | University Hospital, Toulouse | |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI | NCT02066870 | Non-small Cell ... | Icotinib Arsenic trioxid... | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT05816499 | NSCLC Stage IV NSCLC Stage III... NSCLC Stage III... | Cadonilimab Anlotinib Docetaxel | 18 Years - | Shanghai Chest Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
